Clinically advanced non-invasive imaging acquisition for precise prostate cancer detection
OnQ Prostate is an FDA-cleared software solution using Restriction Spectrum Imaging (RSI), a patented diffusion MRI method that has been shown to improve detection, in vivo characterization, and localization of clinically significant cancer.
Improved accuracy for quality reads
Through clear, easy-to-interpret images OnQ™ Prostate empowers collaborative decision-making and enhances targeting for biopsy and therapy. Elevating clinical workflows that use MRI for prostate cancer detection, monitoring, and treatment, it helps bridge the gaps between radiologists and referring physicians.
Detection and prediction
Of clinically significant cancer
Improved tumor conspicuity
And differentiation from non-tumor
Stronger histopathology correlation
Based on Gleason Score
OnQ™ Prostate outputs
OnQ™ Prostate achieves improved PI-RADS accuracy and inter-reader agreement.
Shows areas of restricted diffusion with increased conspicuity compared to acquired and computed high b-value DWI
Automatically fuses the restricted signal with the T2 for anatomic localization.
“This technology has allowed for improved prostate cancer detection by helping distinguish aggressive lesions from normal prostate tissue."
Dr. Michael Liss
MD, Urology, UT San Antonio
“Restriction Spectrum Imaging increases diagnostic confidence particularly in cases with borderline features on standard diffusion-weighted imaging.”
MD Radiology, University of Rochester
“I expect that the utilization of RSI in clinical practice will result in fewer unnecessary biopsies, and greater diagnostic yield of biopsies."
MD Radiology, Weill Cornell Medicine